Savage Brian reported option exercise involving 4,503 derivative units of TEVA PHARMACEUTICAL INDUSTRIES LTD at $34.70 for −$156k on Sep 18, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Interim Chief Legal Officer
Interim Chief Legal Officer
Filed Sep 22, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
−$156,254.10Shares × reported price
Shares traded
4,503Stock Options (right to buy)
Price per share
$34.70Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Sep 18, 2026Option exercise
Filed
Sep 22, 2026, 5:01 PM ET4-day reporting delay
Accession
0001193125-26-398105Code M · Transaction 227735
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Option exercise4,503$34.70$156,254.10Trade 227731
Sep 18, 2026Sell4,503$38.69−$174,221.07Trade 227732
Sep 18, 2026Sell2,525$39.15−$98,841.13Trade 227733
Sep 18, 2026Sell314$38.70−$12,152.99Trade 227734
5 transaction rows in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −4.4%1w ago −5.4%1d ago 0%
Returns since7d +1.6%30d +3.6%90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.